Lookup NU author(s): Judith Weiland,
Dr Alex Elder,
Dr Victoria Forster,
Professor Olaf Heidenreich,
Professor Josef Vormoor
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Over the last 20-30 years CD19 has gained attention as a potential target in the therapy of B-cell malignancies. In particular, targeting CD19 with the bispecific T-cell engager (BiTE) antibody Blinatumomab and T-cells modified by chimeric antigen receptors (CAR) has shown promising efficacy in early phase clinical trials for adults and children with precursor B-cell ALL (BCP-ALL). This review will discuss the rationale behind targeting CD19 in BCP-ALL and its potential importance in BCP-ALL signaling pathways. Pediatr Blood Cancer 2015;62:1144-1148. (c) 2015 Wiley Periodicals, Inc.
Author(s): Weiland J, Elder A, Forster V, Heidenreich O, Koschmieder S, Vormoor J
Publication type: Review
Publication status: Published
Journal: Pediatric Blood & Cancer
Print publication date: 01/07/2015
Online publication date: 08/03/2015
Acceptance date: 16/01/2015
ISSN (print): 1545-5009
ISSN (electronic): 1545-5017